Engineering Strategies to Enhance TCR-Based Adoptive T Cell Therapy

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• T cell receptor (TCR)-based adoptive T cell therapies (ACT) offer broad cancer antigen targeting.
• Current TCR-based ACT faces challenges including functional avidity, MHC restriction, and the tumor microenvironment.

Purpose of the Study:

• To summarize basic, translational, and clinical findings in TCR-based ACT.
• To discuss opportunities and limitations of current TCR-based therapies.
• To highlight innovations poised to advance TCR gene therapy.

Main Methods:

• Review of target antigen characteristics and conventional αβ-TCRs.
• Summary of published clinical trials involving TCR-transgenic T cell therapies.
• Discussion of synthetic biology and genome editing strategies.

Main Results:

• TCRs can target a wide array of cancer antigens.
• Synthetic biology and engineering approaches offer solutions to current limitations.
• Precision genome editing is impacting the next generation of TCR therapies.

Conclusions:

• Innovations in synthetic biology, engineering, and genome editing are crucial for overcoming TCR-based ACT challenges.
• These advancements are expected to significantly improve the efficacy of TCR gene therapy for cancer treatment.